Related Experiment Video
Updated: Sep 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[COVID-19 Vaccines for Patients with Neuroimmunological Diseases]
1Department of Neurology, Tohoku Medical and Pharmaceutical University.
Abstract:
More than 2 years have passed since the outbreak of coronavirus disease 2019 (COVID-19), but there is still no sign that the COVID-19 pandemic has ended. Although vaccines have shown high efficacy against severe acute respiratory syndrome coronavirus 2, a risk of adverse reactions and thrombosis has also been reported. Here we review the current knowledge regarding vaccination in patients with neuroimmunological diseases and those receiving immunosuppressive drugs or disease-modifying therapy.
More Related Videos
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
09:24Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
Published on: April 15, 2014
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Psychoneuroimmunology: Diabetes and Cancer